Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Sees Large Growth in Short Interest

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 26,030,000 shares, an increase of 13.5% from the December 15th total of 22,940,000 shares. Based on an average daily volume of 2,170,000 shares, the days-to-cover ratio is presently 12.0 days.

Institutional Trading of Lineage Cell Therapeutics

Several large investors have recently modified their holdings of LCTX. Defender Capital LLC. grew its position in Lineage Cell Therapeutics by 0.6% during the third quarter. Defender Capital LLC. now owns 5,002,198 shares of the company’s stock valued at $4,528,000 after buying an additional 29,223 shares during the period. Raffles Associates LP boosted its stake in shares of Lineage Cell Therapeutics by 3.4% during the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock worth $4,081,000 after acquiring an additional 150,000 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Lineage Cell Therapeutics by 2.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock valued at $3,331,000 after acquiring an additional 83,274 shares during the period. State Street Corp increased its stake in shares of Lineage Cell Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,608,352 shares of the company’s stock worth $2,361,000 after purchasing an additional 45,483 shares in the last quarter. Finally, MAI Capital Management raised its holdings in Lineage Cell Therapeutics by 2.2% in the 3rd quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock worth $1,516,000 after purchasing an additional 35,907 shares during the period. Institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Stock Up 2.8 %

NYSEAMERICAN:LCTX opened at $0.59 on Friday. The company has a market capitalization of $129.47 million, a price-to-earnings ratio of -4.90 and a beta of 1.18. Lineage Cell Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.61.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. HC Wainwright boosted their price objective on shares of Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. D. Boral Capital restated a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research note on Friday, January 3rd. Finally, Maxim Group dropped their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $4.80.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.